# The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

> **NCT06146725** · — · RECRUITING · sponsor: **Jasper Gerritsen** · enrollment: 564 (estimated)

## Conditions studied

- Glioblastoma
- Glioblastoma, IDH-wildtype
- Glioblastoma Multiforme
- Glioblastoma Multiforme, Adult
- Glioblastoma Multiforme of Brain

## Interventions

- **PROCEDURE:** Tumor resection
- **PROCEDURE:** Tumor biopsy

## Key facts

- **NCT ID:** NCT06146725
- **Lead sponsor:** Jasper Gerritsen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 564 (ESTIMATED)
- **Last updated:** 2023-11-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06146725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06146725, "The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06146725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*